JNJ Buyout Rumor

Quote












Yes. Why do you think the stock shot up last week on Thursday and Friday? A bunch of BSC employees purchasing stock because of the rumor. The information leaked. It's happening. It is why JNJ let go there whole Cordis Cardiology division. It will be a bargain for them.
 






Anonymous said:
Yes. Why do you think the stock shot up last week on Thursday and Friday? A bunch of BSC employees purchasing stock because of the rumor. The information leaked. It's happening. It is why JNJ let go there whole Cordis Cardiology division. It will be a bargain for them.
Click to expand...

Does JNJ want all of BSC or just the cardiology division?
 






Anonymous said:
A post on the Abbott Vascular board claims that JNJ is looking to purchase BSC. Any truth to the rumor?
Click to expand...

Just my opinion...Won't happen...
still a lot of bad blood between J&J & BSC -- Pete Nicholas is too proud to give in to J&J. Only way he would give in is if the sky was falling at BSC --The sky is not falling despite posts on CP from a minority of former/current disgruntled employees. Yes, the stock has been flat for awhile, however, BSC is re-tooling --buying a lot of emerging technologies (Sadra, Atritech, etc) that will pay off in the next 12-18 months. Even if BSC's ablation division was of interest to J&J, BSC wouldn't bite on it. While anything is possible in this world, I would be willing to bet Ray understands the importance of the power of CRM, EP & Atritech technologies(500m-1B market) in the EP lab, selling to 1 customer --the EP.

J&J let go of their Cordis reps b/c their sales were tanking --due to Abbott & BSC owning the stent market with better technology--no other reason. Love the conspiracy theory, although it's a stretch.
 












They will acquire the whole company and then divest certain divisions where they have "monopoly issues." There main reason for purchasing is to get into the IC & CRM space. Obviously, they were in the IC space, but had a dead product with cypher and a dead pipeline. BSX has a solid IC pipeline, so they simply layed off the whole Cordis Cardiology division and will start up again when they acquire BSX. J & J has mounds of cash and wants to play in all medical spaces. The rest of the divisions are just icing on the cake. They will pay less for the whole company then they bid for Guidant in 2006. They are thanking Jim Tobin in a big way.
 






"Sadra, Atritech, etc"

Huh? both are not even close to US launch. Years away............ Simply bought to look attractive imo

Abbott's BVS technology will be the biggest game changer in years so what exactly is BSC's plan to counter?

What % of BSC is stent and CRM? losing share in CRM to go along with a flat market and your stents will likley be obsolete in 2-3 years.

Take the money and run Pete! BTW, the acquisitions are smart in that they give JNJ access to rapidly growing areas ranging from TAVI to renal, etc but boht wont affect the bottom line for some time in terms of tangible sales(EW will likley have only TAVI product for 3-4 years in the US)
 






Anonymous said:
"Sadra, Atritech, etc"

Huh? both are not even close to US launch. Years away............ Simply bought to look attractive imo

Abbott's BVS technology will be the biggest game changer in years so what exactly is BSC's plan to counter?

What % of BSC is stent and CRM? losing share in CRM to go along with a flat market and your stents will likley be obsolete in 2-3 years.

Take the money and run Pete! BTW, the acquisitions are smart in that they give JNJ access to rapidly growing areas ranging from TAVI to renal, etc but boht wont affect the bottom line for some time in terms of tangible sales(EW will likley have only TAVI product for 3-4 years in the US)
Click to expand...

"years away" ... do some homework ...Atritech's Wachman is approved in Europe and will likely launch in the US in mid 2012 (12-18 months from now). 800 patient study completed and showed 38% stroke reduction etc. Do some homework Einstein before spreading bs. Wall Street feels strongly the market is 500M to 1B. AGA (SJM) is 2-3 years behind BSC with "similar" technology (they haven't even started their clinical trial). Go back to your Abbott site and spread your baloney to cool-aid drinkers like yourself.
 












Anonymous said:
Total B.S. There's no truth to this.
Click to expand...

Word @ Cordis is JNJ is going to sell off what they can of Cordis. They cut cardiology sales force, capped the endo reps @ total comp of 150k. Biosense Webster hasn't grown like they would've liked. Cypher sales are flat and they are going to run out of Rx platforms. Nevo trial stopped because the stent won't stay on the catheter. DX catheter backorders, JNJ wants to cut losses and run.
 






Anonymous said:
Word @ Cordis is JNJ is going to sell off what they can of Cordis. They cut cardiology sales force, capped the endo reps @ total comp of 150k. Biosense Webster hasn't grown like they would've liked. Cypher sales are flat and they are going to run out of Rx platforms. Nevo trial stopped because the stent won't stay on the catheter. DX catheter backorders, JNJ wants to cut losses and run.
Click to expand...

You have no idea what you're talking about. Biosense Webster is growing at a furious pace, more than what anybody could have imagined.
 












Anonymous said:
Word @ Cordis is JNJ is going to sell off what they can of Cordis. They cut cardiology sales force, capped the endo reps @ total comp of 150k. Biosense Webster hasn't grown like they would've liked. Cypher sales are flat and they are going to run out of Rx platforms. Nevo trial stopped because the stent won't stay on the catheter. DX catheter backorders, JNJ wants to cut losses and run.
Click to expand...

Thank you for proving once again that these boards are a total waste of time. Most of your post is BS, most notably the $150K cap on Cordis reps.
 






Top Bottom
Back
Quote